Your donation will make a difference:
Cystic Fibrosis Trust

Stopping the Clock campaign timeline

Take a look at the latest updates in our Stopping the Clock campaign for fairer access to precision medicines for people with cystic fibrosis (CF) across the UK.

Campaign timeline

Take a look at our news stories below for more information on each stage of our fight for fairer access to life-changing medicines for people with cystic fibrosis. Use the following colour code to find updates on the treatment you are interested in or view the actions we have taken to promote access to all medicines.

Access to medicines 
Other treatments


  • 28 February - round table meeting at Westminster to be chaired by Ian Austin MP to continue discussions with Vertex about access to Orkambi.
  • 2 February - Vertex announces plans for phase III trials of triple combination therapies that could benefit more than 90% of people with cystic fibrosis.
  • 23 January - Welsh Assembly Petitions Committee decide against a debate on access to Orkambi, but write to the Welsh Health Minister regarding the current Welsh Government's position, ahead of further potential discussions and debates on the issue. 
  • 22 January - Trust meets with Vertex to demand that they act and present a bold deal to make their medicines available across the whole of the UK and released a statement.
  • 10 January - a petition is handed into Welsh Assembly for access to Orkambi in Wales. The topic will be automatically considered for debate. 


  • 11 December - a response is received from Richard Pengelly to the cross-party letter in Northern Ireland.
  • 29 November - the Trust organises an event, sponsored by Ian Austin MP, to get MPs from across all political parties in one room with representatives from the Trust and campaigners to share their own personal stories and highlight why the Stopping the Clock campaign is so vital to those living with cystic fibrosis.
  • 10 November - the Trust sends letters to Jeremy Hunt, Secretary of State for Health and Richard Pengelly, Department of Health Permanent Secretary, calling for a timely resolution to the ongoing negotiations between Vertex and Health and Social Care Northern Ireland. These letters are signed by 66 MLAs in Northern Ireland from a number of different parties.
  • 3 November - phase III trials for a double combination therapy using tezacaftor and ivacaftor have shown positive results for people with two copies of F508del and one copy of F508del and a 'residual function' mutation.
  • 12 October - Wales extends access to Kalydeco for people with an R117H mutation. 
  • 5 September - Vertex issues an update on proposals to increase access to Orkambi.
  • 19 July - Vertex announces promising results from trials into their new triple combination therapy.
  • 26 June - Trust Chief Executive David Ramsden wrote to Vertex and the NHS in all four UK nations appealing to them to reach an agreement on pricing for Orkambi and end the wait. Read the responses from NHS Scotland, NHS Wales, the HSC Board in Northern Ireland and Vertex Pharmaceuticals.
  • 26 June - the Trust holds a day of protests in England, Northern Ireland, Scotland and Wales, to call on Vertex and governments across the UK to agree on an affordable price that can make Orkambi immediately available to those who so desperately need it. Read about the protests
  • 21 March - the Trust meets with the new Health Minister, who states that the Government is still open to a deal, and is looking forward to hearing new proposals from Vertex.


  • 13 December - the Trust holds a parliamentary debate encouraging the Government to help implement the recommendations in the Accelerated Access Review.
  • 5 December - NHS England announces that Kalydeco will be made available to two-to-five-year-olds in England, benefitting around 50 children.
  • 24 November - the Trust launch an e-action ahead of their parliamentary debate on Orkambi.
  • 27 October - Scotland becomes the first of the devolved nations to grant two-to-five-year-olds access to Kalydeco.
  • October - Orkambi negotiations between Vertex, the Government and the NHS get underway.
  • 17 June - NICE gives final rejection of Orkambi for use on the NHS in England - the Trust suggests a solution using the UK CF Registry to give people access while allowing data on its efficacy to be gathered.
  • 19 May - Orkambi and Kalydeco are rejected in Scotland, hundreds of people use the Trust's e-action to contact their MSPs to urge the Scottish Government to support the Trust's solution and have Orkambi and Kalydeco provided to those who need it by the New Medicines Fund.
  • 1 April 6,000 people use the Trust's e-action to contact their MPs in support of the Trust's proposed solution to the issues around providing Orkambi, leading the Government to state it is ready to discuss proposals to allow people access to Orkambi at a cost-effective price. This follows NICE's initial rejection of Orkambi for use in the UK despite evidence of its efficacy, stating cost and a lack of long-term evidence about its benefits.
  • 2 March - Carly Jeavons, a young mother with CF, presents the Trust's petition at Downing Street.
  • 28 January - the Trust launch a petition that 20,000 people go on to sign, calling for the NHS and drug companies to take responsibility for ensuring precision medicines are available to those who need them as soon as possible.


  • December - the CF community take to Twitter to tell Ian Austin MP how much precision medicines mean to them. Ian Austin uses these powerful stories in a parliamentary debate that sees the Government go on record to support the Trust's campaign.
  • November - almost 1,500 passionate campaigners take part in the Trust's survey about what precision medicines mean to them, shaping the Trust's submission to the National Institute for Health and Care Excellence (NICE) as it prepares to consider Orkambi.


Orkambi is the second precision medicine to be licensed in the UK for people with CF and treats the F508del mutation, which around 50% of people with CF have. It is not currently available on the NHS.

More about Orkambi


Kalydeco is the first precision medicine to be available on the NHS and is effective in just under 10% of people with cystic fibrosis. Kalydeco is currently available to every eligible person over the age of two in the UK.

More about Kalydeco

Other precision medicines

A double combination therapy and a triple combination therapy are currently being trialed to see how they could help to treat up to 90% of people with cystic fibrosis. Recent results are positive.

More about other treatments